insights_auto
Outlook: 35.7% bullish·0.0% bearish
Go to analysischevron_right
V2EE34:BVMF
Veeva Systems Inc Bdr
R$56.17
0.00%
(0.00) 1D
Nov 9, 4:56:00 PM GMT-3 · BRL
search
All symbols
No data
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for V2EE34...
Open
R$56.17
High
R$56.17
Low
R$56.17
Mkt. cap
49.61B
Avg. vol.
1.60K
Volume
2.00
52-wk high
R$57.11
52-wk low
R$25.14
Shares outstanding
161.91M
No. of employees
8K
Open
R$56.17
High
R$56.17
Low
R$56.17
Mkt. cap
49.61B
Avg. vol.
1.60K
Volume
2.00
52-wk high
R$57.11
52-wk low
R$25.14
Shares outstanding
161.91M
No. of employees
8K
News stories
From web sources and news partners
Investor's Business Daily
·
9 hours ago
IBD Stock Of The Day, Veeva, Retests Its Buy Point On $6 Billion View
Investing.com
·
16 hours ago
BMO raises Veeva Systems stock price target on growth opportunities
Investing.com
·
17 hours ago
Truist raises Veeva Systems stock price target on growth outlook
Investing.com
·
21 hours ago
BTIG raises Veeva Systems stock price target on AI growth potential
Profile
Veeva Systems Inc., headquartered in Pleasanton, California, provides cloud computing software, data, and consulting services for the life sciences industry. Its products are used to track all aspects of drug development and pharmaceutical manufacturing.
The company has 1,552 customers including Bayer, Boehringer Ingelheim, Eli Lilly and Company, Gilead Sciences, Merck & Co., Novartis, Alkermes plc, Alnylam Pharmaceuticals, bluebird bio, and Idorsia. Wikipedia
About Veeva Systems Inc Bdr
CEOPeter Gassner
Employees7.93K
Founded2007
HeadquartersPleasanton, California, United States
SectorHealth Care
Industry-
Websiteveeva.com
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
- Quarterly
- Annual
All values in USD | Oct 2025 | Jan 2026 | Apr 2026 | Jul 2026 |
|---|---|---|---|---|
Revenue | 811.24M | 835.95M | 882.95M | 927.96M |
Cost of goods sold | 199.46M | 213.48M | 220.92M | 232.01M |
Cost of revenue | 199.46M | 213.48M | 220.92M | 232.01M |
Research and development expenses | 191.88M | 198.79M | 208.32M | 222.92M |
Total research and development expenses | - | - | - | - |
Selling, general, and admin expenses | 179.04M | 177.80M | 180.59M | 198.02M |
Operating expense | 370.92M | 376.60M | 388.91M | 420.93M |
Total operating expenses | 570.38M | 590.08M | 609.84M | 652.94M |
Operating income | 240.85M | 245.88M | 273.11M | 275.02M |
Other non operating income | - | 934.00K | - | - |
EBT including unusual items | 312.79M | 317.54M | 347.53M | 349.53M |
EBT excluding unusual items | 312.79M | 315.70M | 345.74M | 349.53M |
Income tax expense | 76.58M | 73.33M | 86.59M | 76.10M |
Effective tax rate | 24.48% | 23.09% | 24.92% | 21.77% |
Other operating expenses | - | - | - | - |
Net income | 236.20M | 244.20M | 260.94M | 273.43M |
Net profit margin | 29.12% | 29.21% | 29.55% | 29.47% |
Earnings per share | 2.04 | 2.06 | 2.24 | 2.35 |
Interest and investment income | 71.93M | 74.35M | 70.63M | 72.51M |
Interest expense | - | - | - | - |
Net interest expenses | 71.93M | 74.35M | 70.63M | 72.51M |
Depreciation and amortization charges | - | - | - | - |
EBITDA | 250.56M | 254.19M | 284.70M | 285.89M |
Gain or loss from assets sale | - | - | - | - |
Upcoming events